OverviewChartNewsTraderScreen

Morgan Stanley Knock-Out BGNE/  DE000MB80XF1  /

Stuttgart
5/22/2024  4:53:13 PM Chg.+0.18 Bid7:12:29 PM Ask7:12:29 PM Underlying Strike price Expiration date Option type
6.52EUR +2.84% 6.39
Bid Size: 3,750		 6.55
Ask Size: 3,750		 BeiGene Ltd 99.4163 - 12/31/2078 Call
GlobeNewswire 8/6/2020 BeiGene Reports Second Quarter 2020 Financial Results
GlobeNewswire 8/5/2020 BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society fo...
GlobeNewswire 7/27/2020 Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
GlobeNewswire 7/17/2020 BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
GlobeNewswire 7/15/2020 BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
GlobeNewswire 7/13/2020 BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
GlobeNewswire 7/2/2020 BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipe...
GlobeNewswire 7/2/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients wit...
GlobeNewswire 7/1/2020 BeiGene Announces Appointment of Angus Grant as Chief Business Executive
GlobeNewswire 7/1/2020 BeiGene Begins Commercializing XGEVA® (Denosumab) in China
GlobeNewswire 6/19/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination ...
GlobeNewswire 6/18/2020 BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application fo...
GlobeNewswire 6/12/2020 BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Asso...
GlobeNewswire 6/5/2020 BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
GlobeNewswire 6/3/2020 BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refra...
GlobeNewswire 5/29/2020 BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Pa...
GlobeNewswire 5/29/2020 BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patien...
GlobeNewswire 5/26/2020 BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at ...
GlobeNewswire 5/21/2020 BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Appl...
GlobeNewswire 5/20/2020 BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
GlobeNewswire 5/15/2020 BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for...
GlobeNewswire 5/14/2020 BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be ...
GlobeNewswire 5/11/2020 BeiGene Reports First Quarter 2020 Financial Results
GlobeNewswire 4/29/2020 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (A...
GlobeNewswire 4/20/2020 BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination ...